Dupilumab Sustains Long-Term Reduction of Staphylococcus aureus in Patients with Atopic Dermatitis
RAD 2025: Researchers observed a marked reduction and low burden of viable S. aureus on lesional and non-lesional skin after 1 year of dupilumab treatment.
INTEGUMENT-OLE: Roflumilast Cream Maintains Long-Term Disease Control in Pediatric and Adolescent Atopic Dermatitis
RAD 2025: Roflumilast cream significantly improved atopic dermatitis in children and adolescents through 52 weeks, offering a safe, effective treatment option.
Lebrikizumab Maintains Deep Response, QoL Through 3 Years in Atopic Dermatitis Extension Study
RAD 2025: Under lebrikizumab maintenance treatment in week 16 responders, approximately 8 out of 10 achieved almost clear skin up to 3 years.
Roflumilast Cream 0.15% Demonstrates Safety, Tolerability in Individuals With Atopic Dermatitis With Prior Treatment Failures
RAD 2025: Safety and tolerability of roflumilast cream 0.15% was demonstrated in a pooled subgroup analysis of phase 3 study participants unresponsive to or intolerant of previous topical therapy.
Real-World Abrocitinib Study Shows Most Patients Maintain Consistent Dosing in Atopic Dermatitis Treatment
RAD 2025: This unique study design simulates the real-world use of JAK inhibitors in tailored treatment regimens with flexibility to manage AEs.
Patient Survey Highlights Importance of Itch Relief, Personalized Guidance in Atopic Dermatitis Treatment
RAD 2025: More than 80% of people would want, or would consider, a test that would direct them towards a more effective therapy for their AD, according to new data.
Long-Term Roflumilast Data Show Durable Efficacy in Young Children and Adults with Atopic Dermatitis
RAD 2025: Arcutis Biotherapeutics will present promising long-term data on roflumilast cream, focused on effectiveness and safety for treating atopic dermatitis in young children.
Women’s Health Takeaways for Primary Care: Expert Insights from ACOG 2025
Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
ACOG 2025: Joy Baker, MD, discusses the urgent need to prioritize postpartum depression screening, normalize mental health in prenatal care, and strengthen continuity between OB-GYN and primary care.
New Data on Atopic Dermatitis for Frontline Clinicians: RAD 2025 Preview
Preview of 10 new studies on managing atopic dermatitis, including biologics, treatment barriers, and innovative care strategies for clinicians.
Provider Gaps in Postpartum Depression Screening and Management Highlighted in New Study
ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.
Tailoring Weight Management Conversations Across a Woman’s Lifespan
Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.
The Weekly Dose: How Medicaid Policies Impact Postpartum Depression Care
At ACOG 2025, Elizabeth Mollard, PhD, discussed her research on Medicaid PPD screening and coverage policies on PPD diagnosis.
From Screening to Support: How PCPs Can Tackle PPD
ACOG 2025: Joy Baker, MD, urged primary care clinicians to screen early, refer confidently, and help change the statistics on maternal mental health.
Johanna Finkle, MD, on Approaching Weight Loss Discussions with Reproductive-Aged Patients
ACOG 2025: Johanna Finkle, MD, shares strategies to start weight conversations with patients and build clinician confidence in counseling and treatment options.
PPD Screening, Medicaid Coverage, and Access to Care: A Q&A with Elizabeth Mollard, PhD
ACOG 2025: Elizabeth Mollard, PhD, discusses her research on how Medicaid policies influence postpartum depression screening rates.
“I’m Just Tired”: Listening for the Words Patients Actually Use
ACOG 2025: Joy Baker, MD, discusses the importance of listening closely to how patients describe postpartum distress—and to read between the lines.
Laxmi Gannu, MS, Explains a New Study of Clinician's Knowledge of Post Partum Depression
ACOG 2025: The Junonia study was designed to understand gaps in care for women with PPD using surveys of their clinicians and care coordinators.
Nanette Santoro, MD, Highlights Findings on Fezolinetant From Pooled Analysis of Phase 3 Skylight Development Program Trials
The nonhormonal neurokinin-3 receptor antagonist improved menopausal adiposity without appreciable impact on body weight or BMI, Santoro explained at 2025 ACOG meeting.
When We Talk About Perinatal Weight Issues, We Need to Focus on the Whole Person, Johanna Finkle, MD, Reminds Clinicians
ACOG 2025: Pregnant patients may not want to discuss weight gain initially, so focus on overall perinatal health, and use that information to guide more conversation.
